Introduction {#s1}
============

Constipation is a clinically common gastrointestinal dysfunction with a prevalence of 5--20% worldwide ([@B23]). According to the Rome IV criteria, a typical symptom of chronic constipation is difficult, infrequent, or inadequate bowel movement ([@B19]). Individuals with bowel movement every 3--4 days are at a higher risk of colon cancer, hemorrhoids, and other gastrointestinal diseases ([@B27]). Laxatives are widely prescribed as the main means to assist patients in passing stools ([@B18]). However, these treatments have severe side effects. Therefore, development of more efficient and safe therapeutic/preventive agents and methods is still needed.

Traditional Chinese medicine (TCM) formulas have been widely used for the prevention and treatment of digestive diseases for thousands of years. Buzhongyiqi decoction (BZYQD) is a well-known TCM formula first described in Pi Wei Lun, a treatise on digestive system diseases written by the famous Chinese physician Li Gao (1180--1251 A.D. of the Chinese Yuan Dynasty) ([@B10]). BZYQD is comprised of eight herbs ([**Table 1**](#T1){ref-type="table"}) ([@B12]) and has been identified as an effective drug for improving the digestive system function, quality of life, and nutritional status in elderly patients with chronic obstructive pulmonary disease ([@B7]). Moreover, BZYQD is also a representative prescription that is increasingly applied to treat gastrointestinal dysfunction, such as constipation, in China ([@B26]; [@B24]; [@B34]; [@B3]). However, its mechanism of action has not yet been fully investigated.

###### 

Herbal constituents of BZYQD.

  Pharmaceutical name                        Chinese name   Part used          Amount (g)
  ------------------------------------------ -------------- ------------------ ------------
  *Astragalus mongholicus* Bunge             Huangqi        Root               18
  *Glycyrrhiza uralensis* Fisch. ex DC       Gancao         Root and rhizome   9
  *Codonopsis pilosula* (Franch.) Nannf.     Dangshen       Root               9
  *Angelica sinensis* (Oliv.) Diels          Danggui        Root               3
  *Citrus ×* aurantium L.                    Chenpi         Pericarp           6
  *Actaea heracleifolia* (Kom.) J. Compton   Shenma         Rhizome            6
  *Bupleurum chinense* DC.                   Chaihu         Root               6
  *Atractylodes macrocephala* Koidz.         Baizhu         Rhizome            9

Metabolomics represents a powerful discipline concerned with the comprehensive analysis of small molecules to discover biomarkers in biological systems ([@B22]; [@B33]). This method provides holistic insights into changes in the metabolic pathways during disease or drug treatment ([@B28]; [@B35]). Therefore, metabolomics study is in perfect accordance with the holistic approach of TCM, and can provide clues to mechanism of action of TCM ([@B28]; [@B35]). In the current study, the effect of BZYQD on loperamide-induced constipation in a rat model was investigated. Additionally, the underlying molecular mechanism of BZYQD in constipation was explored by serum metabolomics. Our results provide novel insights into the potential role of the herbal medicine BZYQD in treating gastrointestinal dysfunction diseases.

Materials and Methods {#s2}
=====================

Chemical Compounds and Reagents {#s2_1}
-------------------------------

Chromatography-grade acetonitrile was purchased from Merck (Darmstadt, Germany). Water was purified using a Milli-Q water system (Millipore, Bedford, MA, USA). Chromatography-grade acetic acid, formic acid, and methanol were provided by Tedia Company (Fairfield, OH, USA). All the crude drugs including Radix Astragali (Huangqi in China, HQ), Radix Glycyrrhizae (Gancao in China, GC), Rhizoma Atractylodis Macrocephalae (Baizhu in China, BZ), Radix Codonopsis (Dangshen in China, DS), Radix Angelicae Sinensis (Danggui in China, DG), Pericarpium Citri Reticulatae (Chengpi in China, CP), Radix Bupleuri (Caihu in China, CH), and Rhizoma Cimicifugae (Shengma in China, SM) were purchased from Shanghai Kangqiao Chinese Medicine Tablet Co., Ltd (Shanghai, China) and authenticated by Gen Chim Testing Co., Ltd (Shanghai, China). Mosapride was purchased from Sigma-Aldrich (St. Louis, MO, USA).

Preparation and Analysis of BZYQD {#s2_2}
---------------------------------

BZYQD was prepared according to our previously reported method. A mixture of HQ (18 g), DS (9 g), BZ (9 g), DG (3 g), GC (9 g), CP (6 g), SM (6 g), and CF (6 g) was added to 600 ml water and extracted at 100°C for 1 h. The extracted solution was filtered and spray-dried to obtain dry extract powder. The final ratio of BZYQD extract powder to raw herb was 37.80%. The total ion chromatogram of BZYQD extract that measured by LC-MS is shown as [**Figure 1**](#f1){ref-type="fig"}.

![Total ion chromatogram of BZYQD extract in negative-ion mode **(A)** and positive-ion mode **(B)**. 1: Piscidic acid; 2: Ferulic acid; 3: Liquiritin; 4: Hesperidin; 5: 2-feruloylpiscidic acid; 6: Glycyrrhizic Acid; 7: Saikosaponin D; 8: Synephrine; 9: Codonopyrrolidium B; 10: Tryptophan; 11: Nobiletin; 12: 3, 5, 6, 7, 8, 3\', 4\'-heptamethoxyflavone.](fphar-11-00423-g001){#f1}

Animals and Experimental Design {#s2_3}
-------------------------------

Male 8-week-old Sprague--Dawley (SD) rats were provided by the Laboratory Animal Center of Shanghai University of Traditional Chinese Medicine. The animals were housed and acclimatized for one week prior to the experiment in a room at 20--22°C and 60--70% humidity under a 12 h-light and 12 h-dark cycle. All animal experiments were carried out in full compliance with the Guidance of Humane Care and Use of Laboratory and approved by the Committee on the Use of Live Animals for Teaching and Research in the Shanghai University of Traditional Chinese Medicine. Rats were randomly divided into four groups: control (normal control), loperamide, loperamide+BZYQD (1.73 g/kg of BZYQD extract powder), and loperamide+mosapride (positive group, 1.6 mg/kg), with 8 rats per group. Rats of the loperamide, loperamide+BZYQD, and loperamide+mosapride groups were treated with loperamide (4 mg/kg, b. w.), by subcutaneous injection twice per day at 09:00 and at 18:00 h for 1 week, and all the corresponding drugs was orally administered to the rats once daily from the third day. Rats in the control group and loperamide group orally received the normal saline. The scheme of the animal experiment is summarized in [**Figure 2**](#f2){ref-type="fig"}. A 100% survival rate was recorded at the end point of the experiment.

![Scheme of experiment. Buzhongyiqi decoction (BZYQD) treatment commenced on day 3, s.c: subcutaneous injection.](fphar-11-00423-g002){#f2}

Measurement of Gastro-Intestinal Propulsion (GIP) {#s2_4}
-------------------------------------------------

All the groups were exposed to fasting conditions and drank only water on the seventh day. GIP was measured through prepared Chinese ink. Thirty minutes later, all animals were fed with the prepared Chinese ink (10% charcoal in 5% gum Arabic) and were anesthetized. The small intestine was immediately dissected and put on a clean surface. The travelling distance of the charcoal meal from the pylorus was measured. The gastrointestinal propulsion was calculated based on the following formula: GIP = (Distance travelled by charcoal (cm)/total intestinal length (cm) ×100%. Then, the colon tissues were collected for further studies.

Hematoxylin-Eosin Staining {#s2_5}
--------------------------

Small intestine and colon tissues were fixed in 10% formaldehyde, dehydrated, embedded in paraffin, cut into 5-μm-thick sections, and stained with hematoxylin and eosin. Pathological changes were observed using the OlympusBX70 research microscope.

Serum Metabolomics Study {#s2_6}
------------------------

### Sample Preparation {#s2_6_1}

An aliquot of 100 μl acetonitrile containing the internal standards (IS, 10 μg/ml 2-chloro-L-phenylalanine in positive and negative modes) was added to 20 μl of serum samples. After vortex-mixing for 3 min, the mixture was centrifuged for 10 min at 16,000 rpm at 4°C, and 5 μl of the supernatant was injected for UPLC-MS/MS analysis. An equal aliquot from each serum sample was combined and mixed to prepare the quality control (QC) samples. The QC samples were processed by the same method as the other serum samples and analyzed randomly through the analytical batch to ensure the stability of the analytical process.

### Analysis Conditions {#s2_6_2}

Sample analysis was performed using a UPLC-LTQ-Orbitrap system (Thermo Fisher Scientific, San Jose, CA, USA) and the samples were separated using a Waters ACQUITY UPLC BEH C18 column (2.1×100 mm, 1.7 μm) (Waters, Co., Milford, MA, USA). The mobile phases contained water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B). The elution steps were as follows: 10% B from 0.1--2 min, 10--40% B from 2.1--7 min, 40--80% B from 7.1--11 min, 80--90% B from 11.1--15 min, and 90% B for 0.5 min. At 15.5 min, B was adjusted to 10% and the column equilibrated for 4.5 min. The mass spectrometer parameters were as follows: ion spray voltage, 3.8 kV(+) and 3.2 kV(−); capillary and heater temperature, both 350°C; sheath and auxiliary gas flow rate, 45 and 15 psi, respectively; and S-Lens RF level, 60% ([@B17]; [@B28]).

### Data Processing {#s2_6_3}

Data preprocessing, identification of potential biomarkers, and pathway analysis were performed as reported previously ([@B11]; [@B17]). In brief, the raw data of UPLC-LTQ-Orbitrap were imported to SIEVE to perform peak extraction and matching. Retention time, m/z value, and corresponding intensities were recorded. These data were preprocessed as per the rules below: (1) the percentage of valid data in each group must be higher than 80%; (2) the relative standard deviation (RSD) in QC samples must be lower than 30%; (3) the intensities of each variable should be normalized by the intensity of the IS. After preprocessing, data were imported to SIMCA-P version 14.0 (Umetrics, Sweden) to perform principal components analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). The variable importance in projection (VIP) value was calculated in the OPLS-DA model and the Kruskal-Wallis test was conducted. Variables with VIP values more than 1 and P values less than 0.05 were considered potential biomarkers. These potential biomarkers were identified by searching databases such as HMDB (<http://www.hmdb.ca/>), KEGG (<https://www.kegg.jp/>), ChemSpider (<http://www.chemspider.com/>), and mzCloud (<https://www.mzcloud.org/>), and were finally validated by standard substances to confirm their identity.

Immunohistochemistry Analysis {#s2_7}
-----------------------------

Dewaxed, hydrated colon tissue sections were pretreated with antigen retrieval fluid (pH 6.0), incubated with 3% H~2~O~2~ deionized water for 15 min to block endogenous peroxidase, and rinsed with PBS. IL-6 (1:400) and TNF-α (1:400) were added dropwise and samples incubated overnight at 4°C. The sections were immersed in PBS, and an IgG antibody and Fab fragment-HRP multimer were added dropwise. The mixture was incubated at 37°C for 30 min, and the samples were subsequently washed 5 times with PBS for 3 min each time. Samples were rinsed with distilled water, counter stained with hematoxylin, dehydrated with gradient alcohol, cleared with xylene, and sealed with resin. Positive immunostaining in five random visual fields of the slides was evaluated using an Olympus DP72 optical microscope at a magnification of ×200.

Real-Time Polymerase Chain Reaction (PCR) Analysis {#s2_8}
--------------------------------------------------

Total RNA was extracted from colon tissues using Trizol, and cDNA was subsequently synthesized using the Super Script cDNA synthesis kit. Real-time polymerase chain reaction (real-time PCR) was performed using the ABI-StepOnePlus sequence detection system (Applied Biosystems, CA, USA) using the Fast SYBR Green mix kit. The primers used are presented in [**Table 2**](#T2){ref-type="table"}. The relative target mRNA expression levels were calculated using the 2^-ΔΔCt^ method. The expression level of glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) mRNA was used as the endogenous reference control.

###### 

Primers of real-time PCR assay used in this study.

  GeneName                                Specise   Primer sequence (5′-3′)
  --------------------------------------- --------- ---------------------------------------
  *Gapdh*                                 Rat       Forward primer AGGTCGGTGTGAACGGATTTTG
  Reverse primer GGGGTCGTTGATGGCAACA                
  *NF-κB*                                 Rat       Forward primer GACGACACCTCTACACATAGCA
  Reverse primer CCTCATCTTCTCCAGCCTTCTC             
  *IL-6*                                  Rat       Forward primer CCGGAGAGGAGACTTCACAG
  Reverse primer CCATAGTGCAGGAGCGTACAGT             
  *IL-1β*                                 Rat       Forward primer TGACCCATGTGAGCTGAAAG
  Reverse primer GGGATTTTGTCGTTGCTTGT               
  *TNF-α*                                 Rat       Forward primer TGATCCGAGATGTGGAACTG
  Reverse primer CGAGCAGGAATGAGAAGAGG               
  *COX-2*                                 Rat       Forward primer TCTCCAACCTCTCCTACTAC
  Reverse primer GCACGTAGTCTTCGATCACT               

Western Blot Analysis {#s2_9}
---------------------

The colon samples were homogenized in a radioimmunoprecipitation assay buffer. The lysate proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were electro-blotted onto nitrocellulose membranes. The membranes were blocked for 1 h, and then incubated overnight with primary antibodies against p-NF-κB and NF-κB (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA) at 4°C. The membranes were subsequently washed with Tris-buffered saline/0.1% (v/v) Tween-20 and incubated for 1 h with secondary antibodies. After washing the membranes, the protein bands were detected using the FluorChem E image detection system (ProteinSimple, San Jose, CA, USA). β-actin was used as a loading control.

Enzyme Linked Immunosorbent Assay (ELISA) {#s2_10}
-----------------------------------------

The protein levels of IL-1β and IL-6 in rat serum were measured using an ELISA kit (AMEKO Institute of Biotechnology, Shanghai, China) according to the manufacturer\'s instructions.

Statistical Analysis {#s2_11}
--------------------

Data are expressed as the mean ± standard deviation (SD). The statistical differences among study groups were determined by one-way analysis of variance (ANOVA) followed by the least significant difference (LSD). For all comparisons, *P* \< 0.05 was considered a statistically significant difference. Correlation coefficient (r) was determined using the Pearson\'s correlation.

Results {#s3}
=======

Effect of BZYQD on Constipation in Loperamide Induced Rats {#s3_1}
----------------------------------------------------------

The body weight did not differ significantly between loperamide-induced group and normal control group ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). The small intestinal transit rate and number of stools were significantly decreased in loperamide induced group than those in normal control group ([**Figures 3A, B**](#f3){ref-type="fig"}). Treatment with BZYQD markedly increased the small intestinal transit rates and number of stools as compared to those in the loperamide group ([**Figures 3A, B**](#f3){ref-type="fig"}). As compared with normal control group, the epithelial surface of the rat colon was damaged, mucosa was thinner, gland was reduced, goblet cells were reduced, and the inflammatory cells infiltrated in the lamina propria in the loperamide group; these histological damages were significantly ameliorated by BZYQD treatment ([**Figure 3C**](#f3){ref-type="fig"}).

![Effect of BZYQD intervention on loperamide-induced constipation in rats. **(A)** Small intestinal transit rates of rats of Control group, Loperamide, Loperamide + BZYQD, and Loperamide + Mosapride groups. **(B)** Number of stools of rats of Control group, Loperamide, Loperamide + BZYQD, and Loperamide + Mosapride groups. **(C)** Hematoxylin and eosin (H&E)-staining for light microscopy analysis of colon sections in rats of the control group, Loperamide group, Loperamide + BZYQD group, Loperamide + Mosapride groups morphology. Arrow marks pointed to that epithelial surface of the rat colon was damaged, mucosa was thinner, gland was reduced, goblet cells were reduced, and the inflammatory cells infiltrated in the lamina propria in the loperamide group. n = 8; Original magnification ×100 or ×200; data are represented as mean ± SD. ^\#^*P* \< 0.05 versus control group; \**P* \< 0.05versus loperamide group, \*\**P* \< 0.01 versus Loperamide group.](fphar-11-00423-g003){#f3}

Effect of BZYQD on the Metabolism of Rats with Loperamide-Induced Constipation {#s3_2}
------------------------------------------------------------------------------

As observed in the PCA plots, the QC samples were clustered closely under both positive and negative monitoring modes, which suggested a stable analysis method ([**Figures 4A, B**](#f4){ref-type="fig"}). The OPLS-DA results indicated an appreciable separation of the data relating to these three groups ([**Figures 4C, D**](#f4){ref-type="fig"}). After identification and screening, levels of 29 serum metabolites in the loperamide induced group were significantly different from those in the normal control group, and BZYQD treatment reversed levels of 17 of these metabolites ([**Table 3**](#T3){ref-type="table"}). Among these differential metabolites, four were identified using authenticated standards and others were deduced using accurate molecular weights and comparing tandem mass spectrometry fragments with data in metabolomics databases. The levels of metabolites in the three groups are presented as a heatmap ([**Figure 4E**](#f4){ref-type="fig"}). To further explore the metabolic pathways that BZYQD influenced, these metabolites were imported into MetaboAnalyst (<https://www.metaboanalyst.ca/>) to conduct pathway analysis. The related metabolic pathways are listed in [**Figure 5**](#f5){ref-type="fig"} and [**Table 4**](#T4){ref-type="table"}. The metabolic pathways influenced by BZYQD were arachidonic acid (AA) metabolism, biosynthesis of unsaturated fatty acids, ascorbate and aldarate metabolism, alactose metabolism, and inositol phosphate metabolism. According to the p value and --log (p) ([@B31]; [@B28]), arachidonic acid metabolism is one of the main pathways that influenced by BZYQD.

![Effect of BZYQD intervention on serum metabolic profiling in loperamide-treated rats. **(A, B)** PCA score plot in three groups, R^2^X = 0.513, Q^2^ = 0.41 in positive model. R^2^X = 0.567, Q^2^ = 0.279 in negative model. **(C, D)** OPLS-DA score plot in three groups, R^2^X = 0.788, R^2^Y = 0.995, Q^2^ = 0.515 in positive model. R^2^X = 0.544, R^2^Y = 0.918, Q^2^ = 0.487 in negative model. **(E)** Hierarchical clustering heat map of the differential metabolite levels in control (C), loperamide (L), and loperamide + BZYQD groups (B) (n = 8). The heat map indicated that the serum levels of nine metabolites (Green color) were decreased, and eight metabolites (Red color) were increased in loperamide + BZYQD group as compared with loperamide group.](fphar-11-00423-g004){#f4}

###### 

Endogenous metabolites identified in the serum of rats included in this study.

  VIP      Time   Molecular ion   CompMW   Formula             Metabolites
  -------- ------ --------------- -------- ------------------- ------------------------------
  1.0830   8.22   \[M-H\]^-^      352.47   C~20~H~32~O~5~      Prostaglandin E2
  1.6241   8.16   \[M-H\]^-^      304.47   C~20~H~32~O~2~      Arachidonic acid
  2.1715   6.29   \[M-H\]^-^      392.57   C~24~H~40~ O~4~     Chenodeoxycholic acid
  1.2442   6.37   \[M-H\]^-^      424.28   C~24~H~40~O~6~      1beta-Hydroxycholic acid
  1.8625   5.91   \[M-H\]^-^      499.70   C~26~H~45~NO~6~S    Tauroursodeoxycholic acid
  1.2511   8.33   \[M-H\]^-^      180.16   C~6~H~12~O~6~       Inositol
  1.4063   8.89   \[M-H\]^-^      549.37   C~28~H~56~NO~7~P    LysoPC(20:1)
  1.1752   7.97   \[M+H\] ^+^     571.17   C~30~H~52~ NO~7~P   LysoPC(22:4)
  1.9844   5.31   \[M+H\]^+^      131.17   C~6~H~13~NO~2~      Leucine
  2.0029   5.31   \[M+H\]^+^      189.21   C~11~H~11~NO~2~     IpA(Indole-3-propionic acid)
  1.5352   1.11   \[M+H\]^+^      161.20   C~7~H~15~NO~3~      Carnitine
  1.2700   8.70   \[M+H\]^+^      302.22   C~20~H~30~O~2~      Eicosapentanoic acid
  2.6147   6.39   \[M+H\]^+^      356.27   C~24~H~36~O~2~      Ethyl docosahexaenoate
  1.5642   6.14   \[M+H\]^+^      406.27   C~24~H~38~O~5~      7-ketodeoxycholic acid
  1.7325   8.11   \[M+H\]^+^      423.33   C~25~H~45~NO~4~     Linoelaidyl carnitine
  1.3189   7.58   \[M+H\]^+^      467.29   C~22~H~46~NO~7~P    LysoPC(14:0)
  1.7046   7.63   \[M+H\]^+^      541.32   C~28~H~48~NO~7~P    LysoPC(20:5)

![Main pathway analysis associated with metabolites that were influenced by BZYQD.](fphar-11-00423-g005){#f5}

###### 

The metabolic pathways that influenced by BZYQD in loperamide-treated rats.

  Pathway Name                              Total   Hits   p          -log(p)   Impact
  ----------------------------------------- ------- ------ ---------- --------- --------
  Arachidonic acid metabolism               36      2      0.012167   4.409     0.3468
  Biosynthesis of unsaturated fatty acids   42      2      0.016393   4.1109    0.0000
  Ascorbate and aldarate metabolism         9       1      0.043713   3.1301    0.0000
  Galactose metabolism                      26      1      0.12183    2.1052    0.0000
  Inositol phosphate metabolism             28      1      0.13065    2.0353    0.1116
  Glycerophospholipid metabolism            30      1      0.13939    1.9705    0.0444
  Primary bile acid biosynthesis            46      1      0.20667    1.5767    0.0298

Effect of BZYQD on Inflammatory Response in Rats with Loperamide-Induced Constipation {#s3_3}
-------------------------------------------------------------------------------------

As serum metabolomics revealed that the main pathway influenced by BZYQD was AA metabolism, we further investigated the effect of BZYQD on inflammation in loperamide-induced rat colon tissue. As shown in [**Figures 6A, B**](#f6){ref-type="fig"}, level of serum metabolite PGE~2~ was significantly increased in Loperamide group compared to that in the Control group, and it decreased by BZYQD treatment. Additionally, expression of cyclooxygenase 2 (COX-2), the key enzyme that produces PGE~2~ from AA was also increased in Loperamide group and decreased in BZYQD group. Moreover, the serum levels of inflammatory markers, such as IL-1β and TNF-α, were significantly increased in Loperamide group as compared with Control group. However, treatment with BZYQD decreased the serum levels of IL-1β and TNF-α ([**Figures 6C, D**](#f6){ref-type="fig"}). Additionally, since differential metabolites, such as PGE~2~, play an important role in the progression of inflammation, correlation between serum levels of PGE~2~and those of IL-1β and TNF-α were tested using the Pearson\'s correlation. According to the correlation factor (r=0. 4669 or r=0. 4675) and *P*-value (p=0.0214 or p=0.0213), the results indicated serum levels of IL-1β and TNF-α had positive linear correlations with PGE~2~ levels ([**Figures 6E, F**](#f6){ref-type="fig"}). The Pearson\'s correlation method was descripted as previously reported ([@B29]; [@B35]). Additionally, the mRNA and protein expression of IL-1β and IL-6 in rat colon tissue was also investigated by real-time PCR and immunohistochemistry. As shown in [**Figure 7**](#f7){ref-type="fig"}, the mRNA and protein expression of IL-1β and IL-6 was significantly increased in Loperamide group, and it decreased by BZYQD treatment ([**Figure 7**](#f7){ref-type="fig"}). These results suggest that BZYQD treatment decreases loperamide-induced inflammation.

![Effect of BZYQD intervention on serum levels of inflammatory factors in loperamide-treated rats. **(A)** Serum levels of prostaglandin E~2~ (PGE~2~) in each group; **(B)** The mRNA expression of COX-2 in mice colon tissue; **(C)** Serum levels of IL-6 detected using ELISA in each group; **(D)** Serum levels of TNF-α detected using ELISA in each group; **(E)** The correlation between serum levels of IL-6 and serum metabolite PGE~2~; **(F)** The correlation between serum levels of TNF-α and serum metabolite PGE~2~; data are represented as mean ± SD (n = 8). \*\**P* \< 0.01 between two groups. Correlation factor (r) and *P*-value were determined using the Pearson\'s correlation analysis.](fphar-11-00423-g006){#f6}

![Effect of BZYQD intervention on expression of colon inflammatory factors in loperamide-treated rats. BZYQD decreased the mRNA and protein expression of IL-1β and IL-6: **(A)** The mRNA expression of IL-1β of colon tissues that detected by real-time PCR; **(B)** Protein expression of IL-1β of colon tissues that detected using immunohistochemistry; **(C)** Quantification of protein expression of IL-1β of colon tissues. **(D)** The mRNA expression of IL-6 of colon tissues that detected by real-time PCR; **(E)** Protein expression of IL-6 of colon tissues that detected using immunohistochemistry; **(F)** Quantification of protein expression of 6 of colon tissues. Data are represented as mean ± SD. Arrow marks pointed to positive area expression. (n = 5). \*\**P* \< 0.01 between groups.](fphar-11-00423-g007){#f7}

Effect of BZYQD on NF-κB Signaling Pathway in Rats with Loperamide-Induced Constipation {#s3_4}
---------------------------------------------------------------------------------------

PGE~2~ is produced by AA through COX-2, which is regulated by NF-κB signaling pathway. Therefore, the mRNA and protein expression of p65 in rat colon tissue was further investigated by real-time PCR and western blotting. p65 mRNA expression and p65 and p-p65 protein levels were markedly increased in Loperamide group ([**Figure 8**](#f8){ref-type="fig"}) than those in the control group. However, treatment with BZYQD significantly decreased p65 mRNA expression and p-p65 protein levels ([**Figure 8**](#f8){ref-type="fig"}). This result indicated that BZYQD can regulate NF-κB signaling pathway.

![Effect of BZYQD intervention on NF-κB signaling pathway in loperamide-treated rats. **(A)** The mRNA expression of p65 detected through real-time PCR. **(B)** The protein expression of p-p65 and p65 detected by western blot. **(C)** Ratio of protein expression of p-p65 and p65; data are represented as mean ± SD; n = 8 for real-time PCR and n = 3 for western blot. \*\**P* \< 0.01 between groups.](fphar-11-00423-g008){#f8}

Effect of BZYQD on Serum levels of Gastrointestinal Hormone in Rats with Loperamide-Induced Constipation {#s3_5}
--------------------------------------------------------------------------------------------------------

The serum levels of gastrointestinal hormone of motilin and gastrin were detected by ELISA. The serum levels of motilin and gastrin were markedly decreased in Loperamide group ([**Figure 9**](#f9){ref-type="fig"}) than those in the control group. However, treatment with BZYQD significantly increased serum levels of motilin and gastrin ([**Figure 9**](#f9){ref-type="fig"}). This result indicated that BZYQD can promote gastrointestinal motility.

![Effect of BZYQD intervention on serum levels of motilin and gastrin in loperamide-treated rats. Data are represented as mean ± SD; n = 5. \*\**P* \< 0.01 between groups.](fphar-11-00423-g009){#f9}

Discussion {#s4}
==========

BZYQD is a classic Chinese herbal formula used to treat gastrointestinal diseases ([@B7]), but its mechanism of action has not been fully studied. Loperamide is an anti-diarrheal drug commonly used in the clinic, and its mechanism of action mainly involves the inhibition of intestinal peristalsis and intestinal secretion ([@B32]). Loperamide is widely used to establish animal constipation models to study the etiology and pathogenesis of constipation ([@B27]; [@B9]; [@B32]; [@B18]). In this study, BZYQD treatment increased the intestinal propulsion rate and improved the colon tissue pathological damage induced by loperamide in a loperamide-induced rat constipation model. Mosapride is a commonly used drug to treat gastrointestinal dysfunction. Mosapride was reported to improve loperamide-induced constipation in rats ([@B18]). In the current study, mosapride was used as a positive drug, and there was no significant difference between BZYQD and mosapride in improving constipation. Overall, our results indicate that BZYQD has protective effects against loperamide-induced constipation.

Metabolomics reveals molecular mechanism pathway by assessing differences in the production of metabolites or endogenous small molecules ([@B22]). Metabolomics, thus, provides a holistic view of changes in metabolite levels due to drug interventions. TCM comprise a variety of crude herbs that exert a comprehensive therapeutic effect ([@B28]; [@B35]). Metabolomics is very helpful in exploring the mechanisms of action of TCM ([@B28]; [@B35]). In this study, metabolomics was used to analyze the influence of BZYQD on serum metabolites in a loperamide-induced constipation rat model. Our results showed that the levels of 29 metabolites were changed in the loperamide group compared with the control group, and 17 different metabolites were reversed by BZYQD. KEGG pathway analysis revealed that the major pathway that was influenced by BZYQD was the arachidonic acid metabolism, biosynthesis of unsaturated fatty acids, ascorbate and aldarate metabolism, inositol phosphate metabolism. Therefore, the regulation of those metabolic pathways may be key roles in BZYQD against loperamide-induced constipation.

Arachidonic acid metabolism plays an important role in the inflammatory network ([@B20]). AA and prostaglandin E~2~ (PGE~2~) are both important metabolites involved in the AA metabolic pathway. AA is a type n-6 polyunsaturated fatty acid highly represented in the composition of phospholipids; moreover, it is the precursor of eicosanoids, such as PGE~2~, thromboxanes, and leukotrienes, which are long-recognized mediators of inflammation ([@B1]). There have been reports indicating that the increased release of PGE~2~ can trigger an inflammatory response ([@B13]; [@B16]; [@B25]). In the present study, the serum metabolite PGE~2~ was significantly increased in the loperamide-induced group and decreased upon BZYQD intervention. This result suggests that BZYQD administration may alleviate the inflammatory response induced by loperamide in constipation rats. Histopathological results showed that intervention with BZYQD reduced inflammatory cell infiltration and morphological damage in the colons of rats administered loperamide. Further study showed that BZYQD intervention reduced the levels of serum inflammatory factors IL-1β and TNF-α and colonic inflammatory factors IL-1β and IL-6 in constipation rats. Therefore, the above mentioned results also support the results of our metabolomics study. Previous studies have shown that the inflammatory response is closely related to gastrointestinal motility disorders ([@B2]). Infiltration of inflammatory cells into the digestive tract is a major histological change involved in gastrointestinal motility disorders ([@B2]). In addition, the release of inflammatory mediators also leads to changes in gastrointestinal motility ([@B2]). A recent study reported that loperamide-induced rats exhibit a significant colonic inflammatory response, and anti-inflammatory agents help to exert a laxative effect on constipation in these rats ([@B15]). Thus, consistent with our result, this study showed that inflammation may play an important role in the progression of constipation. Our results also suggested that BZYQD can alleviate the inflammatory response induced by loperamide and ameliorate constipation.

AA is catalyzed by COX-2 to produce the metabolite PGE~2~ ([@B25]), while COX-2 expression is regulated by the NF-κB signaling pathway ([@B30]; [@B4]). In this study, we found that BZYQD can inhibit NF-κB phosphorylation in the colon of constipation rats, and down-regulate the expression of COX-2, thereby reducing the level of PGE~2~. Therefore, our results suggest that the regulation of the arachidonic acid pathway by BZYQD may occur through the inhibition of the NF-κB signaling pathway. However, further exploration through future studies is needed. In addition, the release of inflammatory mediators is also known to induce acute inflammatory cell infiltration and promote NF-κB activity ([@B14]; [@B6]; [@B21]). Here, we observed that BZYQD inhibited the activation of the NF-κB pathway, which may also contribute to its protective effect against loperamide-induced constipation.

There have been reported that inositol phosphate is associated with gastrointestinal hormone motilin and gastrin metabolism ([@B5]; [@B8]). In the current study, we have investigated the effect of BZYQD on the serum levels of gastrointestinal hormone. Our results indicated that BZYQD increased the serum levels of gastrointestinal hormone motilin and gastrin. Therefore, those results suggested that treatment with BZYQD may promote the gastrointestinal motility of rats with loperamide-induced constipation.

In conclusion, the results of this study demonstrated that BZTQD intervention exerts a protective effect against loperamide-induced constipation, which may be associated with its role in regulation of multiple metabolic pathways.
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